Ask about this productRelated genes to: IL17A protein
- Gene:
- IL17A NIH gene
- Name:
- interleukin 17A
- Previous symbol:
- CTLA8, IL17
- Synonyms:
- IL-17A, IL-17
- Chromosome:
- 6p12.2
- Locus Type:
- gene with protein product
- Date approved:
- 1993-10-25
- Date modifiied:
- 2019-04-23
Related products to: IL17A protein
Related articles to: IL17A protein
- Interleukin-17A (IL-17A) is a key Th17 cytokine involved in mucosal defense and chronic inflammation and serves as an important biomarker and therapeutic target in autoimmune, cardiovascular, and infectious diseases. Emerging evidence indicates that immune regulation may differ by sex, which may influence disease susceptibility, biomarker interpretation, and treatment response. However, few studies have examined sex-specific determinants of IL-17A. This study aimed to identify the sociodemographic, clinical, and inflammatory correlates of circulating IL-17A, with a specific focus on elucidating sex-specific determinants. - Source: PubMed
Publication date: 2026/05/18
Chisompola DavidLuwaya EmmanuelChakulya MartinChalwe Joseph MPovia Joreen PKirabo AnnetMasenga Sepiso K - Myocarditis is an inflammatory cardiomyopathy characterized by high level of inflammatory cell infiltration and progressive cardiac dysfunction. The underlying pathogenesis involves direct pathogen damage and inflammation-mediated tissue destruction. Previous studies showed the therapeutic potential of Sivelestat (the neutrophil elastase inhibitor) in mice models, but the underlying mechanisms remain elusive. - Source: PubMed
Publication date: 2026/04/30
Ren RuguoWang NingChen ChenYang MiaoLi BinYang YuxuanZhang HangYang BoWu YuGao WeiHou Yuanyuan - To explore the molecular mechanisms underlying cystoid macular edema (CME) through protein-protein interaction (PPI) network analysis, identifying key regulatory proteins, functional modules, and enriched biological pathways relevant to its pathogenesis. - Source: PubMed
Shariati Mehrdad Motamed - Mesenchymal stromal cells (MSCs) have shown enhanced therapeutic efficacy by cytokine pre-activation or licensing. Previous research has shown subconjunctival administration of low-dose allogeneic MSCs can significantly promote an anti-inflammatory phenotype. We report the effects of pro-inflammatory TNF-α/IL-1β MSC licensing, evaluating therapeutic potency in vitro and in a preclinical model of corneal alkali chemical burn. - Source: PubMed
Publication date: 2026/05/16
Canning AoifeDonohoe EllenJohnston ÉannaLynch KevinMoosavizadeh SeyedmohammadWang JieminLeahy MartinTreacy OliverRyan Aideen ERitter Thomas - Sarcoidosis is a systemic granulomatous disease that often affects the lungs, lymph nodes, and skin. The pathological hallmark of sarcoidosis is the formation of epithelioid, non-necrotizing granulomas, with CD4 T-helper (Th) type 1 (Th1), Th17, and Th17.1 cells scattering throughout the granuloma. The CXCL16-CXCR6 axis plays a crucial role in the development of inflammatory diseases. However, the precise role of CXCR6 CD4 T cells in sarcoidosis pathogenesis and their therapeutic potential remain unclear. In this study, we confirmed the enrichment of CXCR6 CD4 T cells in the lesional tissue of sarcoidosis patients and Propionibacterium acnes-induced sarcoidosis-like model mice. Flow cytometric analysis and single-cell RNA sequencing revealed that CXCR6 CD4 T cells exhibited a Th17/Th17.1 phenotype and displayed pro-inflammatory characteristics. By performing cell-cell communication analysis and validating the findings with flow cytometry and CXCL16-blockade experiments, we demonstrated an active crosstalk between CXCR6 CD4 T cells and CXCL16 macrophages in mice. Furthermore, treating mice with an anti-CXCR6 monoclonal antibody effectively reduced the mRNA levels of pro-inflammatory genes, including Nos2, Cxcl9, Cxcl10, Il17a, Tnf, and Ifng. In addition, anti-CXCR6 treatment reduced the abundance of Th17 and Th17.1 cells, which was associated with inhibition of downstream mTORC1 signaling. Finally, anti-CXCR6 treatment suppressed granuloma formation and attenuated collagen deposition in the lungs. Taken together, our findings highlight CXCR6 as a promising therapeutic target for inhibiting granuloma formation and pulmonary fibrosis in sarcoidosis. - Source: PubMed
Publication date: 2026/05/16
Han YueyinLiu MengyuanXu WenxiuLi ZhenJiang DingyuanGeng JingGao ShuweiLi ShifengXie BingbingZhu LiliZhang HongbingCostabel UlrichDai HuapingWang Chen